Introduction  

Definition and clinical features of cervical dystonia (CD)

Cervical dystonia (CD), otherwise known as spasmodic torticollis, is a rare, painful neurological disorder that can occur at any age, though it typically occurs in middle age.¹ Cervical dystonia is a common form of focal dystonia, with its severity varying - symptoms slowly begin until it reaches a point where it doesn’t get noticeably worse.² It causes involuntary contractions of the neck muscles, causing the head to twist or to have other uncommon movements.¹ The contractions may be continuous or spasmic, and may settle without treatment, though this is uncommon and recurrence is likely.³ In fact, there is no current cure for CD, though a study⁴ found that botulinum toxin, a neurotoxin made by the bacterium Clostridium botulinum and widely used to treat neurological disorders,⁵ injected into the affected muscles in CD helps to reduce its symptoms.² 

Undoubtedly, cervical dystonia affects the lives of those who have it. The cause of CD is currently not known, though there have been possible links of genetic susceptibility underlying some cases, as well as other secondary causes, should CD start in infancy or early childhood, which is much rarer than if it began in middle age.¹

Current diagnostic challenges 

If there’s no current cure, is there a definitive diagnostic test for CD?

It turns out, there isn’t one. In fact, clinicians rely on physical examination - observing symptoms of the head twisted in a particular direction, such as the chin toward the shoulder or straight up/down.² Besides that, doctors may suggest blood tests or magnetic resonance imaging (MRI) to rule out any other conditions that may have caused the symptoms shown.³

Why biomarkers matter

With CD having no treatment and no definitive diagnostic testing, it has become more important for biomarkers to be developed. A biomarker, short for biological marker, is an objective indicator that reflects the state or activity of a cell or organism at a specific point in time, and thus is used to measure disease presence or activity.⁶ They offer potential in transforming the therapeutic landscape of CD, which will be further explained further in the article.

Rationale for Biomarker Development in CD 

Benefits

With cervical dystonia having no definitive tests, and now knowing that it can present with a variety of symptoms, this makes CD a disease in which it is ideal disease for developing biomarker-driven improvements. Why? This is because biomarkers can provide a more objective measurement of the disease,⁶ and hence reduce reliance on more subjective measurements - this makes monitoring more standard, allows earlier detection, and can even cause there to be more tailored treatments given to each individual. 

Looking from a more research standpoint, biomarkers also act as standardised endpoints in clinical trials, which can hence accelerate the development of new therapies, as this allows comparison across studies. 

Biomarker categories

There are different types of biomarkers, and they are classified into the following categories:⁷

• Risk - predicts an individual’s risk of developing a disease 
• Diagnostic - confirms a disease presence 
• Prognostic - predicts the disease’s trajectory, or recurrence
• Monitoring - tracks disease status or quantifies body response to a medication or environmental agent
• Predictive - predicts which patients will respond better to specific treatments
• Pharmacodynamic response - upon being given a medical treatment or environmental agent, the biomarker shows that a biological response was produced 
• Safety biomarkers - show the level of toxicity that is present after being exposed to a medical treatment or environmental agent.

Pathophysiology Overview Relevant to Biomarkers  

Understanding the pathophysiology of cervical dystonia is important for biomarker development, as each mechanism offers ways to change it measurably (such as being used for diagnosis or monitoring). This could be structurally, functionally, biochemically or even molecularly, as you will observe later in this passage.

Cervical dystonia has been hypothesised to be due to dysfunction in circuits in the brain that control voluntary movement. These dysfunctions that lead to dystonia occur between the basal ganglia and the thalamo-cortical loop connection. This causes the varying, inappropriate muscle activation patterns seen in CD.⁸ 

It is also important to remember the peripheral changes that can occur due to CD. For example, chronic abnormal neck postures can lead to secondary muscle hypertrophy or weakness, which will, in effect, change proprioception (awareness of body position).⁹ All of these reinforce the abnormal posture and make it hard to correct. 

Neurochemical studies suggest that dystonia involves the striatum - it is known that this area of the brain’s activity is modulated by multiple neurotransmitters, including dopamine. This system involves dopaminergic, GABAergic, and cholinergic neurotransmission, which are dysregulated in dystonia.¹⁰ These changes are much less substantial than compared of other disorders like Parkinson’s.

The interplay of genetic predisposition and environmental triggers (such as peripheral injury or stress) likely shapes disease onset and progression.

Types of Biomarkers Under Investigation  

Neuroimaging biomarkers 

Meta-analyses of MRI studies in idiopathic cervical dystonia (iCD) show overlapping, consistent changes in various key motor control regions - notably the bilateral pre- and postcentral gyri, supplementary motor area, caudate nucleus, thalamus, cerebellum, and cingulate cortex.¹¹ 

Diffusion tensor imaging (DTI) has further detected microstructural white matter alterations. This reflects connection impairments in the cortico-basal ganglia–cerebellar circuits.¹² 

Neurophysiological biomarkers 

Multiple transcranial magnetic stimulation (TMS) studies have shown reduced short-latency intracortical inhibition (SICI) in patients with focal and segmental dystonias. Altogether, these points point toward a fundamental loss of inhibitory control in motor cortex circuits, leading to unwanted movements.¹³ 

Biochemical biomarkers 

Although elevated plasma levels of neurofilament light chain (NfL) were seen in generalised dystonia and cases of dystonia with Parkinsonism, which is consistent with neurodegenerative involvement,¹⁴ further examination of serum NfL levels in CD is required to support this hypothesis. In fact, it was found that serum NfL levels in cervical dystonia do not differ significantly from healthy controls. This supports another hypothesis - that CD may be a functional network disorder rather than a neurodegenerative disease.¹⁵ 

Genetic/molecular biomarkers

To date, and according to what has been found, there has been no specific literature on CD transcriptomic signatures. However, rare gene variants (such as GNAL, ANO3) associated with focal dystonias are promising molecular targets.¹⁶ 

Digital/behavioural biomarkers

There is potential for wearable sensors, motion capture and even AI-driven video analysis to quantify the movement patterns that are present in movement disorder research, offering potential for real-world monitoring capabilities.¹⁷

Summary 

Cervical dystonia (CD) remains a challenging movement disorder to diagnose and monitor, largely due to the absence of definitive laboratory or imaging tests. Current clinical practice relies on observation of abnormal neck postures, tremor, and muscle overactivity, but these features can overlap with other conditions such as essential tremor or Parkinson’s disease, leading to diagnostic uncertainty. Moreover, clinical rating scales used to assess severity and treatment response are subjective, prone to inter-rater variability, and often insensitive to subtle changes. These limitations underline why biomarkers are critical for CD. Objective, reproducible biological measures would allow earlier recognition of disease, more precise monitoring of progression, and greater reliability in evaluating the impact of therapies. For patients, this could translate into timelier treatment and a reduction in misdiagnosis. For clinicians and researchers, biomarkers would provide standardised tools to compare outcomes across studies and accelerate the development of new interventions.

Over the past decade, significant progress has been made in identifying potential biomarker candidates. Neuroimaging has uncovered structural and functional abnormalities in motor and sensory circuits, including altered connectivity within the basal ganglia–cerebellar–cortical loop, which is central to motor control. While these findings are not yet specific enough for routine clinical use, they establish measurable neural signatures of CD that could become more powerful when combined with other modalities. Neurophysiological studies using transcranial magnetic stimulation (TMS) and electromyography (EMG) have consistently demonstrated reduced cortical inhibition and abnormal patterns of muscle co-contraction, reinforcing the concept of impaired motor network regulation. These physiological markers not only offer diagnostic clues but also provide dynamic measures that could be tracked over time.

Biochemical investigations have been shown to be still in their early stages. Blood-based biomarkers such as neurofilament light chain (NfL) have shown utility in distinguishing neurodegenerative disorders, but in CD, they remain within normal ranges, supporting the idea that the condition is a functional network disorder rather than one characterised by widespread axonal loss. Other candidates, including inflammatory cytokines and oxidative stress markers, have shown preliminary associations with CD but require replication in larger cohorts. Genetic contributions, while rare in isolated CD, continue to be explored, with variants in genes such as GNAL and ANO3 offering entry points for molecular biomarker research.

Perhaps the most exciting frontier is digital health. Wearable sensors, smartphone-based motion tracking, and machine learning applied to patient videos can capture fine-grained movement data in real-world environments. These digital biomarkers have already demonstrated sensitivity to treatment effects, such as improvements following botulinum toxin injections, often before traditional rating scales detect change. The scalability and low cost of digital tools make them attractive candidates for clinical translation.

Despite these advances, important gaps remain. Most biomarker studies in CD involve small, single-centre cohorts, limiting generalisability. Standardisation across sites — in imaging protocols, physiological testing methods, or biofluid handling — is lacking, which makes it difficult to compare results. Furthermore, few studies have validated findings longitudinally, so we still do not know which biomarkers best reflect disease progression or predict long-term treatment response. Another challenge is specificity: biomarkers must reliably distinguish CD from other movement disorders to be clinically useful.

The path forward requires large-scale, multicentre collaborations with harmonised methodologies and well-characterised patient populations. Advances in artificial intelligence and data science will play a central role in synthesising these complex datasets into clinically actionable tools. Alongside technical development, regulatory and ethical frameworks must evolve to address issues such as data privacy in digital biomarker collection and management of incidental genetic findings.

In conclusion, biomarker development for cervical dystonia is at an exciting but still formative stage. Progress across neuroimaging, neurophysiology, biochemical research, genetics, and digital health has provided a strong foundation, yet translation into routine clinical practice remains ahead of us. With coordinated research efforts, biomarkers have the potential to transform CD management - delivering earlier diagnosis, more personalised therapy, and more reliable outcome measurement for individuals living with this disabling condition.